Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $175.00 at Bank of America

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by Bank of America from $165.00 to $175.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other brokerages have also recently commented on ASND. StockNews.com cut shares of Ascendis Pharma A/S from a hold rating to a sell rating in a research report on Tuesday, August 13th. Wells Fargo & Company dropped their price target on Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a research report on Wednesday. Cantor Fitzgerald decreased their price objective on Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating for the company in a research report on Wednesday. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They set a buy rating and a $200.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $170.00 to $174.00 and gave the company an overweight rating in a research note on Wednesday, August 21st. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $187.08.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $119.15 on Wednesday. The stock has a market cap of $6.94 billion, a price-to-earnings ratio of -12.40 and a beta of 0.63. The company has a 50 day moving average of $134.38 and a 200-day moving average of $138.20. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in the business. Profund Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after buying an additional 85 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 91 shares during the period. GAMMA Investing LLC boosted its position in shares of Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 102 shares in the last quarter. Rhumbline Advisers increased its stake in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.